Pathway candidateNCBI-verifiedprotein-coding

LIN28B

lin-28 RNA binding posttranscriptional regulator B

NCBI Gene: 389421 Ensembl GeneCards UniProt: Q6ZN17

Pathway candidate — not linked to PFS or PSSD by any record here

LIN28B is in the library because it belongs to the rna processing family. No study, report or commentary in the corpus names it, so a variant in LIN28B is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 6 (rna processing and mirna biogenesis). The protein encoded by this gene belongs to the lin-28 family, which is characterized by the presence of a cold-shock domain and a pair of CCHC zinc finger domains. This gene is highly expressed in testis, fetal liver, placenta, and in primary human tumors and cancer cell lines.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Protein lin-28 homolog B
Function (excerpt): Suppressor of microRNA (miRNA) biogenesis, including that of let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and sequester them in the nucleolus, away from the microprocessor complex, hence preventing their processing into mature miRNA. Does not act on pri-miR21. The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state of embryonic stem cells by preventing let-7-mediated differentiation. When overexpressed, recruits ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to their terminal uridylation and degradation. This activity might not be relevant in vivo, as LIN28B-mediated inhibition of let-7 miRNA maturation appears to be ZCCHC11-independent. Interaction with target pre-miRNAs occurs via an 5'-GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let-7 repression (By similarity).
Subcellular location: Nucleus; Nucleus, nucleolus; Cytoplasm.
Tissue specificity: Expressed at high levels in the placenta and, at mucher lower, in testis and fetal liver. Isoform 1 is only detected in placenta and in moderately and poorly differentiated hepatocellular carcinoma cells (at protein level). Isoform 2 is detected in fetal liver, non-tumor liver tissues, as well as well-differentiated tumor tissues (at protein level). Tends to be up-regulated in triple-negative (ER-,PR-,HER2-) breast tumors, as well as in liver, ovarian, and thyroid carcinomas.

Source: UniProtKB/Swiss-Prot Q6ZN17, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

miRNA biogenesis and RNA handling; epigenetic-adjacent regulation with no direct post-drug-syndrome link established.

Written for the whole rna processing family, not for LIN28B specifically.

Mentioned in 0 corpus records

No corpus record names LIN28B directly yet. It is in the library because it sits in a pathway the corpus tracks (RNA processing).

Also in rna processing and mirna biogenesis

All 11 genes

Browse by family on the gene families page.

Gene summary

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Protein lin-28 homolog B
Function (excerpt): Suppressor of microRNA (miRNA) biogenesis, including that of let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and sequester them in the nucleolus, away from the microprocessor complex, hence preventing their processing into mature miRNA. Does not act on pri-miR21. The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state of embryonic stem cells by preventing let-7-mediated differentiation. When overexpressed, recruits ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to their terminal uridylation and degradation. This activity might not be relevant in vivo, as LIN28B-mediated inhibition of let-7 miRNA maturation appears to be ZCCHC11-independent. Interaction with target pre-miRNAs occurs via an 5'-GGAG-3' motif in the pre-miRNA terminal loop. Mediates MYC-induced let-7 repression (By similarity).
Subcellular location: Nucleus; Nucleus, nucleolus; Cytoplasm.
Tissue specificity: Expressed at high levels in the placenta and, at mucher lower, in testis and fetal liver. Isoform 1 is only detected in placenta and in moderately and poorly differentiated hepatocellular carcinoma cells (at protein level). Isoform 2 is detected in fetal liver, non-tumor liver tissues, as well as well-differentiated tumor tissues (at protein level). Tends to be up-regulated in triple-negative (ER-,PR-,HER2-) breast tumors, as well as in liver, ovarian, and thyroid carcinomas.